Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

COMPASS Pathways (5Y6) Stock Price & Analysis

7 Followers

5Y6 Stock Chart & Stats

€8.25-€0.20(-2.37%)
At close: 5:30 PM GMT+1
€7.5€10€12.5Aug 18Aug 24Sep 15Oct 1Oct 9Oct 27Nov 9
Day’s Range
EUR 8.25 - EUR 8.25
52-Week Range
EUR 4.12 - EUR 13.30
Previous Close
EUR 8.45
Volume
N/A
Average Volume (3M)
432
Market Cap
EUR 1.17B
Enterprise Value
EUR 1.63B
Total Cash (Recent Filing)
EUR 443.98M
Total Debt (Recent Filing)
EUR 54.39M
Price to Earnings (P/E)
―
Beta
0.94
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
-0.36
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Differentiation

A rapid-onset profile, potential durability lasting up to 12 months, and only a few treatments per year could differentiate COMP360 from existing options. If confirmed through approval and real-world use, these attributes may support adoption among patients, clinicians, and payers.

Regulatory And Launch Readiness

The company is advancing a defined regulatory and commercialization pathway, with the NDA nearing completion and launch preparations already underway. This reduces execution time after a potential approval and reflects organizational readiness, although the timeline remains subject to FDA and rescheduling decisions.

Funding Through Launch

The substantial cash balance provides resources to continue clinical development, complete regulatory work, and build commercial infrastructure without an immediate dependence on new financing. Management expects the balance sheet to fund operations through launch and into 2028, supporting strategic continuity.

Bears Say

Pre-Revenue Business Model

COMPASS has not yet converted its clinical program into commercial revenue, leaving profitability structurally negative until approval and launch. The absence of sales means future financial performance depends heavily on regulatory success, market adoption, reimbursement, and the eventual economics of COMP360.

Heavy Cash Burn

Persistent and increasing operating cash outflows show that development and launch preparation consume substantial capital before commercial cash generation begins. Even with reported liquidity, continued burn can reduce financial flexibility and increase the eventual need for financing if commercialization takes longer or costs more than expected.

Complex Access And REMS Execution

A costly REMS, extended monitoring requirements, and an interim reimbursement coding process could make treatment delivery harder for sites and patients. These operational hurdles may slow prescribing and payer adoption, increase launch expenses, and delay the company’s ability to translate clinical demand into sustained revenue.

COMPASS Pathways News

5Y6 FAQ

What was COMPASS Pathways’s price range in the past 12 months?
COMPASS Pathways lowest stock price was €4.12 and its highest was €13.30 in the past 12 months.
What is COMPASS Pathways’s market cap?
COMPASS Pathways’s market cap is €1.17B.
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 110 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Nov 03, 2026. The company reported -€0.278 earnings per share for the quarter, beating the consensus estimate of -€0.321 by €0.044.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -0.36.
How many shares outstanding does COMPASS Pathways have?
COMPASS Pathways has 141,710,360 shares outstanding.
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -€0.278 in its last earnings report, beating expectations of -€0.321. Following the earnings report the stock price went up 1.911%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Hedge funds hold COMPASS Pathways shares: the largest hedge-fund position in COMPASS Pathways is 21,876,668 shares, and hedge funds decreased their holdings by 4.6M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology